Table 1. Clinical covariates.
| Discovery | Replication | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| KORA | GENOA | ARIC | CHS | GeneSTAR | FHS | RS | MESA | WGHS | LURIC | SHIP | |
| N | 3,788 | 417 | 8,815 | 2,939 | 594 | 1,828 | 834 | 2,506 | 27,553 | 921 | 3,229 |
| Mean ± SD† | |||||||||||
| MI follow-up time (y) | 8.44 ± 1.5 | - | 20.8 ± 6.0 | 10.3 ± 6.0 | 6.72 ± 3.6 | 17.9 ± 5.3 | 9.32 ± 3.2 | 6.25 ± 1.1 | 17.5 ± 3.8 | - | 11.1 ± 0.8** |
| CHD follow-up time (y) | - | 10.4 ± 3.6 | 20.0 ± 6.5 | 10.3 ± 5.9 | 6.07 ± 3.2 | 17.9 ± 5.3 | 9.18 ± 3.2 | 6.18 ± 1.2 | 17.4 ± 4.0 | 9.43 ± 2.6 | 11.1 ± 0.8** |
| Age (y) | 49.2 ± 13.9 | 58.6 ± 10.0 | 54.2 ± 5.68 | 72.4 ± 5.4 | 51.1 ± 11.3 | 53.8 ± 10.0 | 72.2 ± 6.8 | 62.7 ± 10.2 | 54.6 ± 7.1 | 60.1 ± 11.5 | 46.4 ± 15.1 |
| BMI (kg/m2) | 27.2 ± 4.7 | 30.6 ± 6.3 | 27.0 ± 4.9 | 26.2 ± 4.4 | 29.3 ± 6.3 | 27.4 ± 4.93 | 26.7 ± 3.8 | 27.7 ± 5.1 | 25.1 ± 6.8 | 27.5 ± 4.4 | 27.0 ± 4.8 |
| Fibrinogen (g/L) | 2.60 ± 0.6 | 3.19 ± 0.8 | 2.95 ± 0.61 | 3.14 ± 0.61 | 3.83 ± 1.1 | 3.14 ± 0.61 | 3.95 ± 0.87 | 3.35 ± 0.70 | 3.59 ± 0.78 | 3.69 ± 0.90 | 2.95 ± 0.68 |
| log(Fibrinogen) | 0.94 ± 0.22 | 1.11 ± 0.36 | 3.97 ± 0.11 | 1.13 ± 0.19 | 1.30 ± 0.27 | 1.12 ± 0.19 | 1.35 ± 0.21 | 1.19 ± 0.20 | 1.25 ± 0.22 | 1.28 ± 0.26 | 1.06 ± 0.22 |
| HDL (mg/dL) | 57.9 ± 17.0 | 52.5 ± 14.3 | 51.1 ± 16.7 | 55.8 ± 15.9 | 52.1 ± 15.8 | 51.3 ± 15.3 | 204 ± 24.5 | 52.4 ± 15.7 | 53.1 ± 16.6 | 41.8 ± 11.7 | 57.0 ± 17.1 |
| LDL (mg/dL) | 137 ± 41.4 | 117 ± 31.0 | 137 ± 37.6 | 134 ± 35.8 | 130 ± 41.6 | 126 ± 33.0 | 104 ± 12.5 | 117 ± 30.3 | 122 ± 37.3 | 121 ± 33.7 | 137.3 ± 44.2 |
| N (%) | |||||||||||
| MI | 109 (2.88) | - | 859 (9.74) | 498 (16.9) | 30 (5.05) | 158 (8.64) | 57 (6.83) | 62 (2.50) | 413 (1.50) | - | 212 (6.5) |
| CHD | - | 77 (18.5) | 1,625 (18.4) | 942 (32.1) | 85 (14.31) | 305 (16.7) | 113 (13.6) | 128 (5.10) | 1,035 (3.76) | 59 (6.41) | 260 (8.0) |
| Sex (male) | 1,854 (48.9) | 156 (37.4) | 3,983 (45.2) | 1,792 (61.0) | 321 (54.0) | 829 (45.0) | 421 (50.5) | 1,308 (52.2) | 0 (0.00) | 499 (54.2) | 1,537 (47.6) |
| Current Smokers | 962 (25.4) | 47 (11.3) | 2,633 (29.9) | 322 (11.0) | 135 (22.8) | 341 (18.7) | 144 (17.3) | 286 (11.4) | 3200 (11.6) | 197 (21.4) | 1,096 (33.9) |
| Former Smokers | 1,262 (33.3) | 157 (37.6) | 2,050 (23.3) | 1,216 (41.4) | 202 (34.0) | 404* | 429 (51.4) | 1,109 (44.4) | 10,096 (36.6) | 273 (29.6) | 1,004 (31.1) |
| Never Smokers | 1,560 (41.2) | 213 (51.0) | 4,109 (46.6) | 1401 (47.7) | 257 (43.3) | 911* | 261 (31.3) | 1,104 (44.2) | 14,233 (51.7) | 451 (49.0) | 1,129 (35.0) |
| Hypertension | 1,079 (28.5) | 310 (74.3) | 2,272 (25.8) | 1549 (52.7) | 261 (43.94) | 563 (30.8) | 204 (24.5) | 1,097 (43.8) | 6,654 (24.2) | 625 (67.5) | 671 (20.8) |
| Type 2 Diabetes | 565 (14.9) | 52 (12.5) | 1,659 (18.8) | 349 (11.9) | 59 (9.93) | 129 (7.10) | 104 (12.5) | 150 (6.70) | 0 (0.00) | 283 (30.7) | 174 (5.4) |
Clinical covariates for all participating cohorts. KORA did not have incident CHD data and thus did not participate in these analyses. GENOA and LURIC had too few incident MI cases for analysis. ANOVA and Chi-squared tests showed significant differences across cohorts for all clinical covariates with P < 0.001 for all tests. BMI = body mass index; CHD = coronary heart disease; HDL = high-density lipoprotein cholesterol; LDL = low-density lipoprotein cholesterol; MI = myocardial infarction; NA = not available
* For FHS 172 individuals were not current smokers but were not distinguished as former vs never smokers thus percentages were not computed for these categories and the N for those with information is given.
** For SHIP only interval censored data was available. Follow-up time represents the time from initial exam to final exam.
† Continuous variables are summarized as the mean ± standard deviation while binary variables are summarized as the sample size "N" and percentage of samples for a given level of the variable